Pfizer executives said Tuesday they are confident of strong demand for the company's Covid-19 antiviral treatment amid easing pandemic rules
The US pharmaceutical giant, reporting surging first-quarter profits based on a big jump in revenues from its Covid-19 vaccine, said its Paxlovid treatment for the virus would be a valuable means for governments to limit the severity of outbreaks as they ease social distancing and masking rules.
"People are tired of the repeated booster, so it is extremely important to come to a vaccine that could be a yearly vaccine," Bourla told analysts on a conference call, adding that while the company has made progress on this front,"it's not technically easy to achieve." But the company confirmed its full-year revenue forecast of about $100 billion, which is an approximately 23 percent increase on the 2021 level. More than half the revenues are expected to come from the Covid-19 vaccine and therapeutic.
The company expects to produce 120 million courses of the Paxlovid oral pills in 2022, with distribution programs scaling up in the United States and other markets. "What we're also seeing is that we don't have any inventory on hand," Hwang said."Every dose that we produce is being shipped out."
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pfizer sees high demand for COVID-19 pill as profits jumpThe US pharmaceutical giant, reporting surging first-quarter profits based on a big jump in revenues from its COVID-19 vaccine, said its Paxlovid treatment for the virus would be a valuable means for governments to limit the severity of outbreaks as they ease social distancing and masking rules.
Read more »
Ignore latest Covid-19 surge at your perilREADER LETTER | The most troubling aspect of the current surge is that we are unsure of the speed of infection and its lethality. Could the strains mutate into a variant that renders current vaccines obsolete?
Read more »
Africa’s Travel Indaba: Only 37% get full salary, 470 000 tourism jobs lost to Covid-19Africa’s Travel Indaba: Only 37% get full salary, 470 000 tourism jobs lost to Covid-19 The tourism industry has been stunted by Covid-19 but after two years Africa’s Travel Indaba began this week in a bid to rebuild.
Read more »
NICD monitoring COVID-19 subvariant as cases in the country continue to riseOver the past week the country saw a sharp uptick in new cases, but the number of deaths remained relatively low.
Read more »
New Covid-19 scare hits Shanghai and BeijingStreets are quiet and residents have to show negative coronavirus tests to enter venues
Read more »
Aspen Covid-19 vaccine plant risks closure after no orders – executive'If we don't get any kind of vaccine orders, then clearly there'll be very little rationale for retaining the lines that we're currently using for production.'
Read more »